Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
← catalyst calendarNCT06369467 · readout in 377 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
6actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-17 | actual | When the study began enrolling |
| Primary completion | 2027-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Food Allergy
Interventions
- Drug: linvoseltamab — also filed as REGN5458
- Drug: dupilumab — also filed as Dupixent®, REGN668
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events (TEAEs)
measured From the initial first dose of linvoseltamab through the end of week 30
Severity of TEAEs
measured From the initial first dose of linvoseltamab through the end of week 30
Incidence of Adverse Event of Special Interest (AESIs)
measured From the initial first dose of linvoseltamab through the end of week 30
Severity of AESIs
measured From the initial first dose of linvoseltamab through the end of week 30
Incidence of Serious Adverse Events (SAEs)
measured From the initial first dose of linvoseltamab through the end of week 30
Severity of SAEs
measured From the initial first dose of linvoseltamab through the end of week 30
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed